Cataract Surgery, Inflammation
Conditions
Keywords
PREUNI0710, cataract
Brief summary
Is the primary objective of this investigation to compare the clinical efficacy of the drug test - Ster ® (prednisolone 1% ophthalmic suspension - Union Chemicals) in the comparator - Fort ® Pred (prednisolone 1% ophthalmic suspension - Allergan) in the control of postoperative inflammation in cataract surgery by phacoemulsification through periodic measurement of efficiency scores (number of cells in the anterior chamber, the presence of fibrin in the anterior chamber, conjunctival hyperemia, corneal edema and Descemet folds).
Detailed description
The secondary objective is to compare the safety data observed during the study period, ie will be assessed the frequency and intensity of adverse reactions and compared statistically between groups.
Interventions
DRUGSter
prednisolone 1% ophthalmic suspension
DRUGPred Fort
prednisolone 1% ophthalmic suspension
Sponsors
Azidus Brasil
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who agree with all study procedures and sign, by his own free will, IC; * Adult patients, regardless of gender, ethnicity or social status, with good mental health; * Patients who present at screening visit, a clinical diagnosis of cataract with an indication for corrective surgery with phacoemulsification technique.
Exclusion criteria
* Patients with a history or clinical diagnosis of other eye diseases such as glaucoma, corneal ulcers, scarring, and uveitis; * Patients with known hypersensitivity to any component of the drug under investigation; * Patients who have made use of systemic corticosteroids within 15 days before surgery; * Patients who have made use of topical corticosteroids in the 7 days before surgery; * Patients who have made use of systemic antibiotics in the 15 days preceding surgery; * Patients who have made use of topical antibiotics in the 7 days before surgery; * Patients presenting abnormality, at the discretion of the principal investigator in the following ophthalmic examinations Preoperative slit-lamp examination, measurement of intraocular pressure (applanation tonometry) and examination of background, other than the underlying disease (cataract); * Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of clinical efficacy between the test and comparator drugs by measuring periodic scores of efficacy in established clinical parameters. | 28 days of treatment. | We will evaluate the clinical parameters of number of cells in the anterior chamber, the presence of fibrin in the anterior chamber, conjunctival hyperemia, corneal edema and Descemet folds.The treatment will last for 28 days following the conduct of routine postoperative cataract. There will be a total of 04 returns after surgery and with them 07, 14, 21 and 28 days. On each return, will register the change of parameters of efficacy and safety. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of safety data observed during the study period by assessing frequency and intensity of adverse reactions, compared statistically between groups. | 28 days of treatment. | The treatment will last for 28 days following the conduct of routine postoperative cataract. There will be a total of 04 returns after surgery and with them 07, 14, 21 and 28 days. On each return, will register the change of parameters of efficacy and safety. |
Countries
Brazil
Outcome results
None listed